Earnings ·
Glaukos reports Q3 net sales of $211.0M and raises full-year guidance to $785M
GKOSGLAUKOS Corp
Glaukos Corporation reported record third-quarter 2026 net sales of $211.0 million, a 58% increase year-over-year, driven by strong adoption of iDose TR in the U.S. glaucoma segment and the commercial launch of Epioxa in corneal health. The company achieved non-GAAP diluted earnings per share of $0.47 and raised its full-year 2026 net sales guidance to a range of $775 million to $785 million, up from the previous estimate of $680 million to $700 million. Additionally, management introduced preliminary 2027 net sales guidance targeting $1 billion in revenue. Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing novel therapies for glaucoma, corneal disorders, and retinal diseases.